|

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

RECRUITINGSponsored by Alnylam Pharmaceuticals
Actively Recruiting
SponsorAlnylam Pharmaceuticals
Started2020-08-01
Est. completion2030-10-12
Eligibility
SexFEMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05040373

Summary

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Eligibility

Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy

Exclusion Criteria:

* There are no exclusion criteria for participation in this program.

Conditions3

Heart DiseaseHereditary Transthyretin-mediated (hATTR) AmyloidosisPolyneuropathy

Locations1 site

Clinical Trial Site
Iowa City, Iowa, 52242

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.